<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170159_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>SE-NOVOPROD-369386</safetyreportid>
		<primarysourcecountry>SE</primarysourcecountry>
		<occurcountry>SE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130117</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130117</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>E2b Differences Report</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb>ID 124898</authoritynumb>
		<primarysource>
			<reportercountry>SE</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>69</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientsex>1</patientsex>
			<resultstestsprocedures>On an unknown date laboratory tests included: Alanine aminotransferase 4.43 (units unspecified) ref interval is less than 1.20 and test results has been 4.43 - 1.73 - 3.71.- ukat/L)), Aspartate aminotransferase 2.01 (units unspecified) ref interval is less than 0.76 and test result has been 2.01 - 0.78 - 1.88  ukat/L)).</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Prostate cancer metastatic</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Transaminasis elevated</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Transaminases increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Transaminases increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120808</reactionstartdate>
				<reactionfirsttime>317</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Alanine aminotransferase</testname>
				<testresult>4.43</testresult>
				<testunit>N/A</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Aspartate aminotransferase</testname>
				<testresult>2.01</testresult>
				<testunit>N/A</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NovoNorm</medicinalproduct>
				<obtaindrugcountry>SE</obtaindrugcountry>
				<drugbatchnumb>UNKNOWN</drugbatchnumb>
				<drugauthorizationnumb>20-741</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>065</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Product used for unknown indication</drugindication>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>Repaglinide</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NovoNorm</medicinalproduct>
				<obtaindrugcountry>SE</obtaindrugcountry>
				<drugbatchnumb>Unknown</drugbatchnumb>
				<drugauthorizationnumb>20-741</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>065</drugadministrationroute>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>Repaglinide</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ZYTIGA</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>065</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Prostate cancer metastatic</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110926</drugstartdate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ABIRATERONE ACETATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ZYTIGA</medicinalproduct>
				<drugbatchnumb>Unknown</drugbatchnumb>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>065</drugadministrationroute>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121107</drugenddate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ABIRATERONE ACETATE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This serious regulatory authority case was received through the Swedish Medicines products agency (MPA) reported by a pharmacist from Italy reported by a health care professional nos (not otherwise specified) from Sweden concerns a 69-year- old male patient who was treated with NovoNorm (repaglinide) on unknown dates for unknown indication and experienced "transaminases elevated" beginning on 08-AUG-2012.

Non Novo Nordisk suspect drug included Zytiga (abiraterone acetate) from 26-SEP-2011 to 07-NOV-2012.

Medical history included metastased prostate cancer.

On 08-AUG-2012 the patient experienced transaminases elevated. The Novonorm dose was raised during that time and was lowered again. It was reported that for a week in OCT-2012, Zytiga was "deponated" and when Zytiga was introduced again this resulted in a raise in transaminases and Zytiga was seponated on 07-NOV-2012. It was reported that the issue was elevation in transaminasis occurred after long time use of Zytiga.

On an unknown date laboratory tests included: Alanine aminotransferase 4.43 (units unspecified) ref interval is less than 1.20 and test results has been 4.43 - 1.73 - 3.71.- ukat/L)), Aspartate aminotransferase 2.01 (units unspecified) ref interval is less than 0.76 and test result has been 2.01 - 0.78 - 1.88  ukat/L)).

Action taken to NovoNorm was reported as dose decreased.

The overall outcome of the event was reported as recovered.</narrativeincludeclinical>
				<reportercomment>Causality is stated to be possibly related but this is an umbrella evaluation for event and both products</reportercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
